Sean Brynjelsen - Mar 3, 2023 Form 4 Insider Report for Eton Pharmaceuticals, Inc. (ETON)

Role
President & CEO, Director
Signature
/s/ JAMES R. GRUBER
Stock symbol
ETON
Transactions as of
Mar 3, 2023
Transactions value $
$0
Form type
4
Date filed
3/3/2023, 03:10 PM
Previous filing
Sep 23, 2022
Next filing
Feb 15, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ETON Stock Option (Right to buy) Award $0 +350K +21.88% $0.00 1.95M Mar 3, 2023 Common Stock 350K $3.47 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Option was approved by the Compensation Committee of the Board of Directors as of February 20, 2023 and approved by the full Board of Directors on March 3, 2023.
F2 The Shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on February 20, 2027.

Remarks:

The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.